Extended-Release Amphetamine Tablets for Fast Onset and 13-Hour Effect
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a quick-acting, stable, extended release amphetamine product suitable for patients who have difficulty swallowing whole tablets and capsules, with a formulation that provides a fast onset of therapeutic effect and maintains a prolonged therapeutic effect without altering the release profile when split or chewed.
Innovation Solution
The composition includes a combination of immediate and modified release amphetamine components, with a faster onset immediate release component and a slower onset immediate release component, both bound to cation exchange resins, coated with a pH-independent barrier coating, providing a single plasma concentration peak and a therapeutic effect lasting at least 13 hours, suitable for chewable and orally disintegrating tablets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If amphetamine is formulated as immediate-release tablets, then fast onset of therapeutic effect is achieved, but duration of action is limited to about 3 hours
Solution Approach 1:
The amphetamine formulation is segmented into multiple release components: an immediate-release component for fast onset and an extended-release component for prolonged duration. This segmentation allows the single tablet to deliver amphetamine in different kinetic profiles, resolving the contradiction between fast onset and long duration.
Solution Approach 2:
The formulation employs periodic release patterns where amphetamine is delivered in an initial rapid phase followed by a sustained prolonged phase. This periodic action pattern matches the clinical need for both immediate symptom relief and extended therapeutic coverage.
2Duration of action of moving object
If amphetamine is formulated as extended-release capsules (Adderall XR), then duration of action is extended to about 7 hours, but onset of therapeutic effect is delayed
Solution Approach 1:
The tablet formulation segments amphetamine release into distinct kinetic phases through different physical forms (chewed portion for immediate release, swallowed portion for extended release), eliminating the delay in onset while maintaining extended duration.
Solution Approach 2:
The formulation includes an immediate-release component that acts preliminarily to provide fast onset of therapeutic effect before the extended-release component takes over for prolonged duration, preventing the delay seen in conventional extended-release formulations.
3Ease of operation
If amphetamine tablets are made chewable for patients with swallowing difficulties, then ease of operation is improved, but release profile may be altered
Solution Approach 1:
The tablet is segmented into chewable and swallowable portions with different amphetamine release characteristics. The chewable portion provides immediate release suitable for patients with swallowing difficulties, while the swallowable portion maintains extended release properties, preserving overall release profile stability while improving ease of operation.
Solution Approach 2:
Different regions of the tablet have different properties: one portion is formulated to be chewable with immediate release characteristics, while another portion is formulated for swallowing with extended release characteristics. This local quality differentiation allows the tablet to accommodate patient needs without compromising release profile integrity.
4Adaptability or versatility
If d-amphetamine and l-amphetamine are released at different rates, then adaptability to different therapeutic needs is improved, but manufacturing precision is compromised
Solution Approach 1:
The formulation segments the two enantiomers into different release compartments: d-amphetamine in the immediate-release chewable portion and l-amphetamine in the extended-release swallowable portion. This segmentation provides therapeutic adaptability while maintaining precise manufacturing control over each component's release profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves a stable, extended release of amphetamine with a single plasma concentration peak, suitable for patients with swallowing difficulties, maintaining therapeutic effect for up to 13 hours without altering the release profile when split or chewed, and minimizing adverse effects.
Implementation Method 1
both bound to cation exchange resins
Implementation Method 2
coated with a pH-independent barrier coating, providing a single plasma concentration peak
Data Source
AI summary
An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine-cation exchange resin complex-matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and/or the uncoated amphetamine-cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.